Xingsheng Hu

机构：Shenyang Pharmaceutical University, Guangxi University, Hunan University, Chinese Academy of Medical Sciences & Peking Union Medical College · ORCID：0000-0002-5325-4691

发表论文 26 篇 · 总被引 327 次 · h-index 7

代表论文

• Allele Frequency–Adjusted Blood-Based Tumor Mutational Burden as a Predictor of Overall Survival for Patients With NSCLC Treated With PD-(L)1 Inhibitors (2019 · Journal of Thoracic Oncology · 被引 93)
• Prevalence and clinical significance of pathogenic germline BRCA1/2 mutations in Chinese non-small cell lung cancer patients (2019 · Cancer Biology and Medicine · 被引 57)
• Circular RNA profiling identified as a biomarker for predicting the efficacy of Gefitinib therapy for non-small cell lung cancer (2019 · Journal of Thoracic Disease · 被引 40)
• Silence of lncRNA MIAT-mediated inhibition of DLG3 promoter methylation suppresses breast cancer progression via the Hippo signaling pathway (2020 · Cellular Signalling · 被引 38)
• Erratum to Prevalence and clinical significance of pathogenic germline <i>BRCA1/2</i> mutations in Chinese non-small cell lung cancer patients (2020 · Cancer Biology and Medicine · 被引 29)
• A phase I trial of an oral subtype-selective histone deacetylase inhibitor, chidamide, in combination with paclitaxel and carboplatin in patients with advanced non-small cell lung cancer (2016 · Chinese Journal of Cancer Research · 被引 29)